Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non–small-cell lung cancer
R Pérez-Soler - Clinical lung cancer, 2004 - Elsevier
Abstract Erlotinib (OSI-774; Tarceva™) is an orally available, highly specific epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor. The results of 3 phase II studies with …
growth factor receptor (EGFR) tyrosine kinase inhibitor. The results of 3 phase II studies with …
Low-dose erlotinib treatment in elderly or frail patients with EGFR mutation–positive non–small cell lung cancer: A multicenter phase 2 trial
S Miyamoto, K Azuma, H Ishii, A Bessho… - JAMA …, 2020 - jamanetwork.com
Importance Although the efficacy of epidermal growth factor receptor tyrosine kinase
inhibitors forEGFRgene mutation–positive non–small cell lung cancer is well established …
inhibitors forEGFRgene mutation–positive non–small cell lung cancer is well established …
[HTML][HTML] A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR. 21
Introduction BR. 21 demonstrated significant survival benefit for non-small cell lung cancer
patients receiving erlotinib compared with placebo. We undertook to characterize, by …
patients receiving erlotinib compared with placebo. We undertook to characterize, by …
Review of erlotinib in the treatment of advanced non-small cell lung cancer
Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy
M Tiseo, C Gridelli, S Cascinu, L Crinò, FV Piantedosi… - Lung Cancer, 2009 - Elsevier
BACKGROUND: Erlotinib demonstrated significantly prolonged survival versus placebo in
patients with advanced NSCLC who had progressed after standard chemotherapy. TRUST …
patients with advanced NSCLC who had progressed after standard chemotherapy. TRUST …
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma …
PA Jänne, X Wang, MA Socinski, J Crawford… - Journal of clinical …, 2012 - ascopubs.org
Purpose Erlotinib is clinically effective in patients with non–small-cell lung cancer (NSCLC)
who have adenocarcinoma, are never or limited former smokers, or have EGFR mutant …
who have adenocarcinoma, are never or limited former smokers, or have EGFR mutant …
[HTML][HTML] Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy
Objective To assess the cost-effectiveness of erlotinib versus supportive care (placebo)
overall and within a predefined rash subgroup in elderly patients with advanced non-small …
overall and within a predefined rash subgroup in elderly patients with advanced non-small …
Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials
F Petrelli, K Borgonovo, M Cabiddu, S Barni - Anti-cancer drugs, 2011 - journals.lww.com
Three randomized trials (SATURN, ATLAS and IFCT-GFPC 0502) have demonstrated that
the oral antiepidermal growth factor receptor tyrosine kinase inhibitor erlotinib can improve …
the oral antiepidermal growth factor receptor tyrosine kinase inhibitor erlotinib can improve …
Erlotinib as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2: A SWOG phase II trial (S0341)
PJ Hesketh, K Chansky, AJ Wozniak, P Mack… - Journal of Clinical …, 2007 - ascopubs.org
7536 Background: Patients (pts) with advanced NSCLC and PS 2 have an inferior survival
compared with good PS pts. Single agent and combination chemotherapy have been used …
compared with good PS pts. Single agent and combination chemotherapy have been used …
Erlotinib as first-line treatment for untreated advance stage NSCLC with good prognosis
WL Akerley - Journal of Clinical Oncology, 2006 - ascopubs.org
7178 Background: Erlotinib demonstrated improved survival in previously treated NSCLC,
but did not affect survival in untreated NSCLC when used with concurrent chemotherapy. A …
but did not affect survival in untreated NSCLC when used with concurrent chemotherapy. A …